Enzo Biochem, Inc.
New York Stock ExchangeTotal Valuation
Enzo Biochem, Inc. carries a market capitalization of 16.44M, placing it among publicly traded companies globally. Its enterprise value stands at -5.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 16.44M |
| Enterprise Value | -5.70M |
Share Statistics
Enzo Biochem, Inc. currently has 52.24M shares outstanding.
| Shares Outstanding | 52.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Enzo Biochem, Inc. trades at a trailing price-to-earnings ratio of 0.81. The price-to-sales ratio is 1.08, and the price-to-book ratio stands at -0.11.
| PE Ratio | 0.81 |
| PS Ratio | 1.08 |
| PB Ratio | -0.11 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | -2.10 |
| P/OCF Ratio | -2.10 |
Enterprise Valuation
The EV/Sales ratio of 1.06 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 0.62 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.06 |
| EV / EBITDA | 0.48 |
| EV / EBIT | 0.62 |
| EV / FCF | N/A |
Financial Position
Enzo Biochem, Inc. maintains a current ratio of 3.04, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.04 |
| Quick Ratio | 2.59 |
| Debt / Equity | 6.73 |
| Debt / EBITDA | -0.37 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -25.59 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.33 |
Stock Price Statistics
Enzo Biochem, Inc.'s stock has declined approximately -71.21101% over the past 52 weeks. The 50-day moving average sits at 0.47, while the 200-day moving average is 0.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | -71.21101% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Enzo Biochem, Inc. generated 29.10M in revenue and converted that into -21.31M in net income, yielding earnings per share of -0.15. EBITDA reached -8.56M, while operating income came in at -9.93M.
| Revenue | 29.10M |
| Gross Profit | 13.02M |
| Operating Income | -9.93M |
| Pretax Income | -7.60M |
| Net Income | -21.31M |
| EBITDA | -8.56M |
| EBIT | -9.93M |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
Enzo Biochem, Inc. holds 40.30M in cash and equivalents against 3.14M in total debt, resulting in a net debt position of -40.08M. Total book value stands at -298.82M, with working capital of 35.04M providing operational flexibility.
| Cash & Cash Equivalents | 40.30M |
| Total Debt | 3.14M |
| Net Debt | -40.08M |
| Equity (Book Value) | -298.82M |
| Book Value Per Share | -5.76 |
| Working Capital | 35.04M |
Cash Flow
Enzo Biochem, Inc. produced -14.96M in operating cash flow over the past twelve months.
| Operating Cash Flow | -14.96M |
| Capital Expenditures | N/A |
| Free Cash Flow | -14.96M |
| FCF Per Share | -0.29 |
Margins
Enzo Biochem, Inc. operates with a gross margin of 44.74, reflecting its pricing power and cost economics. The operating margin of -34.14 and net profit margin of -73.25 provide insight into operational efficiency.
| Gross Margin | 44.74 |
| Operating Margin | -34.14 |
| Pretax Margin | -26.11 |
| Profit Margin | -73.25 |
| EBITDA Margin | -29.42 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 29.17 |
| FCF Yield | -47.57 |
Stock Splits
Enzo Biochem, Inc.'s most recent stock split took place on October 21, 2004 with a 20:21 split ratio.
| Last Split Date | 10/21/2004 |
| Split Ratio | 20:21 |
Scores
Enzo Biochem, Inc. posts an Altman Z-Score of -4.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.74 |